BFS
SLXP

Bradley Foster & Sargent’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Bradley Foster & Sargent’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4,470
Closed -$551K – 369
2014
Q2 		$551K Sell
4,470
-275
-6% -$30.4K 0.03% 235
2014
Q1 		$492K Buy
+4,745
New +$486K 0.03% 242

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bradley Foster & Sargent's SLXP Position: Q3 2014 in Review

Bradley Foster & Sargent sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q3 2014, closing a stake of 4,470 shares — an estimated $551K sold.

Bradley Foster & Sargent first reported a position in SLXP in Q1 2014 and held it in 2 quarters. The position peaked at $551K in Q2 2014. 348 funds tracked by Wall St. Rank hold SLXP as of Q3 2014.

  • Bradley Foster & Sargent reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q3 2014 after selling out during the quarter.
  • Bradley Foster & Sargent sold 4,470 SALIX PHARMACEUTICALS LTD DEL shares in Q3 2014, an estimated $551K.
  • Bradley Foster & Sargent first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q1 2014 and held it in 2 quarters.
  • Bradley Foster & Sargent's SALIX PHARMACEUTICALS LTD DEL position peaked at $551K in Q2 2014.
  • 348 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q3 2014.

Based on Bradley Foster & Sargent's 13F filing for Q3 2014, filed 7 Nov 2014.